|
Sign In to gain access to subscriptions and/or personal tools.
|
TNF  DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome
M Blank
Center for Autoimmune diseases, Department of Medicine ‘B’, Sheba Medical Center, Tel-Hashomer, Israel
I Krause
Center for Autoimmune diseases, Department of Medicine ‘B’, Sheba Medical Center, Tel-Hashomer, Israel
G Wildbaum
Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
N Karin
Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Y Shoenfeld
Center for Autoimmune diseases, Department of Medicine ‘B’, Sheba Medical Center, Tel-Hashomer, Israel, shoenfel{at}post.tau.ac.il
Naked DNA encoding TNFa was introduced to BALB/c mice with experimental antiphospholipid syndrome (APS) induced by b2GPI. Administration of naked DNA encoding TNFa resulted in the generation of immunological memory to its gene product, associated with elevated circulating anti-TNFa antibodies. Enriched IgG fraction of the mouse anti-TNFa was biologically active since it prevented endothelial cell activation by TNFa, e.g., inhibition of monocyte adhesion to activated endothelial cells (HUVEC). Mice immunized with b2GPI, vaccinated with TNFa DNA at an early stage of disease development, showed decreased titres of circulating anti-b2GPI antibodies as compared to the group of mice vaccinated with a control naked DNA. The reduction of anti-phospholipid antibody production was followed by amelioration of the foetal loss, increased platelet count to normal values as well as normalization of the prolonged aPTT. APS mice which were introduced to the TNFa DNA vector at a later stage of the disease development, showed less improvement in their clinical manifestations. The current study suggests a way in which a DNA vaccine can be employed for induction of a protective immunity in experimental APS.
Key Words: anti-ß2glycoprotein I autoimmunity • antiphospholipid syndrome • DNA vaccination • tumor necrosis factor
Lupus, Vol. 12, No. 7,
546-549 (2003)
DOI: 10.1191/0961203303lu399oa
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Izhak, G. Wildbaum, W. Uri, Y. Shaked, J. Alami, D. Dumont, A. Stein, and N. Karin
Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial Manner
J. Immunol.,
January 15, 2010;
184(2):
1092 - 1101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Shoenfeld, P. L. Meroni, and R. Cervera
Antiphospholipid syndrome dilemmas still to be solved: 2008 status
Ann Rheum Dis,
April 1, 2008;
67(4):
438 - 442.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Neumann, T. Tschernig, D. Popa, A. Schmiedl, G. P. de Lema, K. Resch, and M. U. Martin
Injection of IL-12- and IL-18-encoding plasmids ameliorates the autoimmune pathology of MRL/Mp-Tnfrsf6lpr mice: synergistic effect on autoimmune symptoms
Int. Immunol.,
December 1, 2006;
18(12):
1779 - 1787.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Goldberg, Y. Zohar, G. Wildbaum, Y. Geron, G. Maor, and N. Karin
Suppression of Ongoing Experimental Autoimmune Encephalomyelitis by Neutralizing the Function of the p28 Subunit of IL-27
J. Immunol.,
November 15, 2004;
173(10):
6465 - 6471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Goldberg, G. Wildbaum, Y. Zohar, G. Maor, and N. Karin
Suppression of Ongoing Adjuvant-Induced Arthritis by Neutralizing the Function of the p28 Subunit of IL-27
J. Immunol.,
July 15, 2004;
173(2):
1171 - 1178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
